SCHEMBL1035848

SCHEMBL1035848

CC(=O)OCCCP(C(=O)c1c(C)cc(C)cc1C)C(=O)c1c(C)cc(C)cc1C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.38
TNKS2 Q9H2K2 1/20 0.37
KDM4E B2RXH2 3/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
ESR1 P03372 1/20 0.32
ELANE P08246 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
RAD52 P43351 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
KMT2A Q03164 1/20 0.31
CNR1 P21554 1/20 0.31
CNR2 P34972 1/20 0.31
CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1036237 0.94 ALDH1A1 (0.36) ALDH1A1TNKS2KDM4EAPOBEC3AAPOBEC3G
SCHEMBL1037184 0.84 LMNA (0.38) ALDH1A1KDM4ESMN1; SMN2L3MBTL1MEN1
SCHEMBL691938 0.78 HPGD (0.34) ALDH1A1KDM4ESMN1; SMN2L3MBTL1MEN1
SCHEMBL12956843 0.76 HPGD (0.37) KDM4EESR1ELANESMN1; SMN2L3MBTL1
SCHEMBL1036230 0.75 CNR2 (0.41) ALDH1A1KDM4EAPOBEC3AAPOBEC3GRAD52
SCHEMBL12956434 0.74 LMNA (0.40) ALDH1A1KDM4ESMN1; SMN2L3MBTL1MEN1
SCHEMBL1033311 0.74 CA12 (0.44) ALDH1A1TNKS2ELANESMN1; SMN2LMNA
SCHEMBL2711699 0.72 GAA (0.32) ALDH1A1SMN1; SMN2L3MBTL1MEN1LMNA
SCHEMBL15637145 0.72 ALDH1A1 (0.31) ALDH1A1MEN1KMT2A
SCHEMBL20636994 0.72 NPSR1 (0.40) ALDH1A1KDM4ESMN1; SMN2L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814891-B1 BISACYLPHOSPHANES AND THEIR USE AS PHOTOINITIATORS; PROCESS FOR PREPARING ACYLPHOSPHANES BASF SE (DE) 2011-01-26 EP disclosed
EP-1814891-B1 BISACYLPHOSPHANES AND THEIR USE AS PHOTOINITIATORS; PROCESS FOR PREPARING ACYLPHOSPHANES BASF SE (DE) 2011-01-26 EP disclosed
US-7687657-B2 Process for preparing acylphosphanes and derivatives thereof CIBA SPECIALITY CHEMICALS CORPORATION (US) 2010-03-30 US disclosed
US-7687657-B2 Process for preparing acylphosphanes and derivatives thereof CIBA SPECIALITY CHEMICALS CORPORATION (US) 2010-03-30 US disclosed
US-7687657-B2 Process for preparing acylphosphanes and derivatives thereof CIBA SPECIALITY CHEMICALS CORPORATION (US) 2010-03-30 US disclosed
US-20080004464-A1 Process for Preparing Acylphosphanes and Derivatives Thereof IGM GROUP B.V. (NL) 2008-01-03 US disclosed
US-20080004464-A1 Process for Preparing Acylphosphanes and Derivatives Thereof IGM GROUP B.V. (NL) 2008-01-03 US disclosed
US-20080004464-A1 Process for Preparing Acylphosphanes and Derivatives Thereof IGM GROUP B.V. (NL) 2008-01-03 US disclosed
EP-1814891-A1 PROCESS FOR PREPARING ACYLPHOSPHANES AND DERIVATIVES THEREOF Ciba Specialty Chemicals Holding Inc. (CH) 2007-08-08 EP disclosed
WO-2006056541-A1 PROCESS FOR PREPARING ACYLPHOSPHANES AND DERIVATIVES THEREOF CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004464-A1 Process for Preparing Acylphosphanes and Derivatives Thereof ME2, ME3, MEP1A ALDH1A1 248/4885TNKS2 1526/4885KDM4E 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.